Evidence map›Paper›PMID 35215249›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Predicting Anticancer Drug Resistance Mediated by Mutations.

Yu-Feng Lin, Jia-Jun Liu, Yu-Jen Chang, Chin-Sheng Yu, Wei Yi, Hsien-Yuan Lane, Chih-Hao Lu

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. The Employment of GeneraNutrients · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yu-Feng LinDepartment of Medical Laboratory Science and Biotechnology, Asia University, Taichung 41354, Taiwan.ORCID 0000-0003-1998-3310
Jia-Jun LiuThe Ph.D. Program of Biotechnology and Biomedical Industry, China Medical University, Taichung 40402, Taiwan.
Yu-Jen ChangThe Ph.D. Program of Biotechnology and Biomedical Industry, China Medical University, Taichung 40402, Taiwan.
Chin-Sheng YuDepartment of Information Engineering and Computer Science, Feng Chia University, Taichung 40201, Taiwan.
Wei YiDepartment of Medical Laboratory Science and Biotechnology, Asia University, Taichung 41354, Taiwan.
Hsien-Yuan LaneGraduate Institute of Biomedical Sciences, China Medical University, Taichung 40402, Taiwan.ORCID 0000-0003-2162-8174
Chih-Hao LuThe Ph.D. Program of Biotechnology and Biomedical Industry, China Medical University, Taichung 40402, Taiwan.ORCID 0000-0002-8363-6244

Funding

China Medical University, Taiwan CMU110-S-35
6 · The paper itself

Abstract

Cancer drug resistance presents a challenge for precision medicine. Drug-resistant mutations are always emerging. In this study, we explored the relationship between drug-resistant mutations and drug resistance from the perspective of protein structure. By combining data from previously identified drug-resistant mutations and information of protein structure and function, we used machine learning-based methods to build models to predict cancer drug resistance mutations. The performance of our combined model achieved an accuracy of 86%, a Matthews correlation coefficient score of 0.57, and an F1 score of 0.66. We have constructed a fast, reliable method that predicts and investigates cancer drug resistance in a protein structure. Nonetheless, more information is needed concerning drug resistance and, in particular, clarification is needed about the relationships between the drug and the drug resistance mutations in proteins. Highly accurate predictions regarding drug resistance mutations can be helpful for developing new strategies with personalized cancer treatments. Our novel concept, which combines protein structure information, has the potential to elucidate physiological mechanisms of cancer drug resistance.

Indexed as

cancer drugdrug resistancefeature selectionmachine learningpersonalized therapeuticsprotein structuresingle amino acid variation

Identifiers

PMID35215249
PMCPMC8878306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.